InMode Ltd (STU:154)
€ 16.81 0.21 (1.27%) Market Cap: 1.24 Bil Enterprise Value: 587.59 Mil PE Ratio: 9.22 PB Ratio: 1.77 GF Score: 64/100

Inmode Ltd at UBS Global Healthcare Conference (Virtual) Transcript

May 18, 2020 / 12:20PM GMT
Matthew Charles Taylor
UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices

Okay. Good morning. Thanks, everyone, for joining us for our Global Virtual Health Care Conference here at UBS. I'm Matt Taylor, the U.S. medical supplies and devices analyst. And I'm really pleased to kick off the conference with management from InMode. We've got several members of the management team joining us on the line this morning, including Moshe Mizrahy, who's the CEO and Chairman; Yair Malca, the CFO. We've also got Shakil Lakhani, who's the President of the North American operations and Dr. Spero Theodorou, the Chief Medical Officer. So guys, thanks very much for joining us this morning.

And InMode is a technology-driven aesthetics company that we have covered since its IPO, last year's successful IPO. And what really stands out about the company is its innovation, its focus on safety and generating data around its products. And it really shows in the results. They've been growing really strongly and taking market share right up until the COVID disruption, and we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot